Fernando Aguirre - CVS Health Independent Director
| CVS Stock | USD 59.96 0.95 1.61% |
Director
Mr. Fernando G. Aguirre is Independent Director of the Company. He was a director at Aetna since 2011. Mr. Aguirre served as President and Chief Executive Officer from January 2004 to October 2012 and Chairman from May 2004 to October 2012 of Chiquita Brands International, Inc. . Prior to joining Chiquita, Mr. Aguirre worked for more than 23 years in brand management, general management and turnarounds at The Procter Gamble Company . Mr. Aguirre began his PG career in 1980, serving in various capacities including President and General Manager of PG Brazil, President of PG Mexico, Vice President of PGs global snacks and US food products, and President of global feminine care. In July 2002, Mr. Aguirre was named President, special projects, reporting to PGs Chairman and Chief Executive Officer, working on strategy. He served as a director of Coveris from 2014 to 2015, Levi Strauss from 2010 until August 2014, and CocaCola Enterprises Inc. from 2005 to 2010 since 2018.
| Age | 64 |
| Tenure | 6 years |
| Address | One CVS Drive, Woonsocket, RI, United States, 02895 |
| Phone | 401 765 1500 |
| Web | https://www.cvshealth.com |
Fernando Aguirre Latest Insider Activity
Tracking and analyzing the buying and selling activities of Fernando Aguirre against CVS Health stock is an integral part of due diligence when investing in CVS Health. Fernando Aguirre insider activity provides valuable insight into whether CVS Health is net buyers or sellers over its current business cycle. Note, CVS Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell CVS Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Fernando Aguirre six days ago Acquisition by Fernando Aguirre of 2364 shares of CVS Health at 57.1 subject to Rule 16b-3 | ||
Fernando Aguirre over a month ago Acquisition by Fernando Aguirre of 827 shares of Synchrony Financial at 49.88 subject to Rule 16b-3 |
CVS Health Management Efficiency
The company has Return on Asset of 0.0237 % which means that on every $100 spent on assets, it made $0.0237 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.067 %, implying that it generated $0.067 on every 100 dollars invested. CVS Health's management efficiency ratios could be used to measure how well CVS Health manages its routine affairs as well as how well it operates its assets and liabilities. At this time, CVS Health's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.06 in 2024, whereas Return On Capital Employed is likely to drop 0.08 in 2024. At this time, CVS Health's Intangibles To Total Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.33 in 2024, whereas Other Assets are likely to drop slightly above 4.8 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Timothy Flynn | UnitedHealth Group Incorporated | 64 | |
| Richard Zoretic | Molina Healthcare | 62 | |
| Robert Ditmore | Centene Corp | 86 | |
| Frank DAmelio | Humana Inc | 63 | |
| Orlando Ayala | Centene Corp | 64 | |
| Tommy Thompson | Centene Corp | 78 | |
| William Trubeck | Centene Corp | 74 | |
| Roman Martinez | Cigna Corp | 71 | |
| Karen Katz | Humana Inc | 64 | |
| David Steward | Centene Corp | 68 | |
| John Partridge | Cigna Corp | 71 | |
| Richard Schapiro | Molina Healthcare | 65 | |
| Garrey Carruthers | Molina Healthcare | 80 | |
| Richard Gephardt | Centene Corp | 79 | |
| Kimberly Ross | Cigna Corp | 56 | |
| Glenn Renwick | UnitedHealth Group Incorporated | 64 | |
| Dale Wolf | Molina Healthcare | 66 | |
| David Feinberg | Humana Inc | 58 | |
| Lori Robinson | Centene Corp | 62 | |
| William McDonald | Humana Inc | 64 | |
| Valerie Rice | UnitedHealth Group Incorporated | 58 | |
Management Performance
| Return On Equity | 0.067 | ||||
| Return On Asset | 0.0237 |
CVS Health Corp Leadership Team
Elected by the shareholders, the CVS Health's board of directors comprises two types of representatives: CVS Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CVS. The board's role is to monitor CVS Health's management team and ensure that shareholders' interests are well served. CVS Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CVS Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Ludwig, Independent Director | ||
| Sreekanth MD, Executive Officer | ||
| David Dorman, Independent Chairman of the Board | ||
| Shawn Guertin, Chief Financial Officer, Executive Vice President | ||
| Mary Schapiro, Independent Director | ||
| FACEP MD, VP Officer | ||
| Fernando Aguirre, Independent Director | ||
| Laurence McGrath, Senior Relations | ||
| Laurie Havanec, Chief People Officer, Executive Vice President | ||
| Norman Greve, Chief Officer | ||
| C Brown, Independent Director | ||
| NancyAnn DeParle, Independent Director | ||
| David CEBS, Executive Caremark | ||
| Tilak Mandadi, Data, Digital | ||
| Thomas Cowhey, Executive CFO | ||
| JeanPierre Millon, Independent Director | ||
| Alecia DeCoudreaux, Independent Director | ||
| William Weldon, Independent Director | ||
| Larry McGrath, Sr Relations | ||
| Samrat Esq, Chief VP | ||
| Joshua Flum, Executive Vice President, Chief Strategy and Business Development Officer | ||
| Heidi Capozzi, Executive Officer | ||
| Troyen Brennan, Executive Vice President Chief Medical Officer | ||
| Prem Shah, Executive Vice President, Chief Pharmacy Officer and Co-President of Retail | ||
| Lisa Bisaccia, Chief Human Resource Officer, Executive Vice President | ||
| Karen Lynch, President, Chief Executive Officer, Director | ||
| Thomas Moriarty, Executive Vice President, General Counsel, Chief Policy and External Affairs Officer | ||
| Katerina Guerraz, Chief VP | ||
| Tony White, Independent Director | ||
| Anne Finucane, Independent Director | ||
| Vijay Patel, Senior CoFounder | ||
| James Clark, Senior Vice President - Controller, Chief Accounting Officer | ||
| Eva Boratto, Chief Financial Officer, Executive Vice President | ||
| David Falkowski, Executive Officer | ||
| Prem PharmD, Group President | ||
| Jonathan Roberts, Chief Operating Officer, Executive Vice President | ||
| Gustavo Giraldo, Head Benefits | ||
| Daniel Finke, Executive Vice President and Presidentident - Health Care Benefits Segment | ||
| Larry Merlo, President, Chief Executive Officer, Director | ||
| Alan Lotvin, Executive Vice President and Presidentident - CVS Caremark | ||
| Neela Montgomery, Executive Vice President and President - CVS Pharmacy/Retail | ||
| Alan MD, Ex Services | ||
| Roger Farah, Independent Director | ||
| Sheryl Burke, Chief Responsibility | ||
| MPP MD, Senior President | ||
| Michelle Peluso, Executive Vice President, Chief Customer Officer and Co-President of Retail |
CVS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CVS Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.067 | ||||
| Return On Asset | 0.0237 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 147.28 B | ||||
| Shares Outstanding | 1.26 B | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 82.91 % | ||||
| Number Of Shares Shorted | 21.85 M | ||||
| Price To Earning | 42.99 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for CVS Stock Analysis
When running CVS Health's price analysis, check to measure CVS Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CVS Health is operating at the current time. Most of CVS Health's value examination focuses on studying past and present price action to predict the probability of CVS Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CVS Health's price. Additionally, you may evaluate how the addition of CVS Health to your portfolios can decrease your overall portfolio volatility.